(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 February 2023 (16.02.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/017252 A1

(51) International Patent Classification:
A61P 17/00 (2006.01) *A61K 39/00* (2006.01)
A61P 37/02 (2006.01)

(21) International Application Number:
PCT/GB2022/052070

(22) International Filing Date:
09 August 2022 (09.08.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2111492.1	10 August 2021 (10.08.2021)	GB
2115152.7	21 October 2021 (21.10.2021)	GB
2204211.3	24 March 2022 (24.03.2022)	GB
2204291.5	25 March 2022 (25.03.2022)	GB

(71) Applicant: **KYMAB LIMITED** [GB/GB]; The Bennet Building (B930), Babraham Research Campus, Cambridge CB22 3AT (GB).

(72) Inventors: **PORTER-BROWN, Ben**; Sanofi, Patent Department, 54 rue La Boétie, 75008 Paris (FR). **QUARATINO, Sonia**; Sanofi, Patent Department, 54 rue La Boétie, 75008 Paris (FR). **SAINSON, Richard C A**; Sanofi, Patent Department, 54 rue La Boétie, 75008 Paris (FR). **POWELL, John**; Empanoply Limited, 28 Short Road, Stretham, Ely CB6 3LS (GB).

(74) Agent: **HEY, Fiona Jane**; Potter Clarkson, The Belgrave Centre, Talbot Street, Nottingham Nottinghamshire NG1 5GG (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: TREATMENT OF ATOPIC DERMATITIS




FIG. 2A

(57) Abstract: The present invention relates to methods of treating Atopic Dermatitis in a human subject comprising administering a therapeutically effective amount of an anti-OX40L antibody, or antigen-binding fragment thereof, wherein the antibody or fragment thereof is administered via injection. Also provided are anti-OX40L antibodies, or antigen-binding fragments thereof, glass vials, drug delivery devices, prefilled syringes, microinfusors, pen delivery devices, autoinjectors and kits comprising an anti-OX40L antibody, or antigen-binding fragment thereof for use in such methods.

WO 2023/017252 A1

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*